Gurvinder Singh Rekhi, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gurvinder Singh Rekhi, PhD


Gurvinder Singh Rekhi, PhD
Director, R&D,
Elan Drug Delivery, Inc.

Gurvinder Singh Rekhi, PhD, is currently director of research and development at Élan Drug Inc. in Gainesville, Georgia, managing the activities of the formulation and analytical development, scale-up/transfer, and validation of controlled release dosage forms. He is responsible for regulatory submissions for three NDAs, and he represents the company in contract negotiations, scientific/technical presentations, and intellectual property.

Rekhi is currently an adjunct assistant professor of pharmaceutics at the University of Maryland, School of Pharmacy, as well as an associate professor at the Massachusetts College of Pharmacy. Rekhi also serves as an advisory board member for the Center for Drug Delivery Research at Mercer University, Southern School of Pharmacy.

Rekhi is a member of professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), APhA, CRS, and Rho Chi Pharmaceutical Honor Society. He serves as an editorial board member of Pharmaceutical Technology and ad hoc reviewer for several pharmaceutical journals. He has served as a committee member on one MS, five PhD dissertations and directed two post-doctoral fellows. He has published and presented scientific papers in the US and at international conferences, and he holds numerous patents from the US Patent Office and several EU countries. He has co-authored chapters in the NABPLEX Pharmacy Review Book and the Handbook of Pharmaceutical Granulation Technology.

Rekhi received his B. Pharm. (1983) from Bombay College of Pharmacy, India. He obtained his MS (1986), BS (1989), and PhD (1991) degrees in Pharmaceutics and Industrial Pharmacy from Massachusetts College of Pharmacy. Rekhi is a registered pharmacist in the states of Connecticut, Maryland, and Georgia.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here